Concepedia
Statistics
Publications
9
Citations
262
H-Index
Active since
2002
Affiliations
Dana-Farber Cancer Institute(Current)
Pfizer (United States)
HJ Burstein is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.
Publications per year
2002–2025
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)
Kathy D. Miller, HJ Burstein, Anthony Elias et al. · Journal of Clinical Oncology · 2005 · 75 citations
Medicine, Oncology, Pharmacology +2
Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.
HJ Burstein, Yan Sun, AR Tan et al. · Cancer Research · 2009 · 47 citations
Medicine, Oncology, Pharmacology +15
Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
SM Tolaney, WT Barry, CT Dang et al. · Cancer Research · 2013 · 36 citations
Medicine, Oncology, Pharmacology +17
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
Erin M. Olson, Nancy U. Lin, Pamela J. DiPiro et al. · Annals of Oncology · 2011 · 29 citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Bathsheba's Breast: Women, Cancer and History
HJ Burstein · JAMA · 2002 · 25 citations
Medicine, History, Oncology +8
1–5 of 9